SYRE Q3 2018 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$12M

Net Income

-$12M

EPS (Diluted)

$-13.55

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$71M

Total Liabilities

$8M

Stockholders' Equity

$64M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$1M	-100.0%
Gross Profit	$0	$0	—
Operating Income	-$12M	-$8M	-53.1%
Net Income	-$12M	-$8M	-51.3%